These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 27866953)

  • 1. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
    Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
    Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A feasibility study of using advanced external beam techniques to create a vaginal cuff brachytherapy-like endometrial boost plan.
    Grelewicz Z; Zerrusen B; Sathiaseelan V; Zhang H
    Med Dosim; 2018 Spring; 43(1):30-38. PubMed ID: 28886961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric comparison of vaginal vault brachytherapy vs applicator-guided stereotactic body radiotherapy with volumetric modulated arc therapy and helical tomotherapy for endometrium cancer patients.
    Yildirim BA; Dolek Y; Guler OC; Arslan G; Onal C
    Med Dosim; 2019 Winter; 44(4):332-338. PubMed ID: 30551844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric feasibility of stereotactic body radiation therapy as an alternative to brachytherapy for definitive treatment of medically inoperable early stage endometrial cancer.
    Jones R; Chen Q; Best R; Libby B; Crandley EF; Showalter TN
    Radiat Oncol; 2014 Jul; 9():164. PubMed ID: 25059785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose volume analysis of radiotherapy for inoperable patients with stage I-II endometrial carcinoma.
    Ohkubo Y; Kato S; Kiyohara H; Tsuruoka I; Tamaki T; Noda SE; Ohno T; Nakano T
    J Radiat Res; 2011; 52(5):666-73. PubMed ID: 21857147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
    Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
    J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing organ-at-risk doses for high-dose-rate vaginal brachytherapy between three different planning workflows.
    Gruhl JD; Zheng D; Longo JL; Enke C; Wahl AO
    Brachytherapy; 2017; 16(2):373-377. PubMed ID: 28039010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dosimetric comparison of Volumetric Modulated Arc Therapy (VMAT) and High Dose Rate (HDR) brachytherapy in localized cervical cancer radiotherapy.
    Wali L; Helal A; Darwesh R; Attar M
    J Xray Sci Technol; 2019; 27(3):473-483. PubMed ID: 30958322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Image-based 3D treatment planning for vaginal cylinder brachytherapy: dosimetric effects of bladder filling on organs at risk.
    Hung J; Shen S; De Los Santos JF; Kim RY
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):980-5. PubMed ID: 22138458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 2D vs. 3D dosimetry for Rotte 'Y' applicator high dose rate brachytherapy for medically inoperable endometrial cancer.
    Beriwal S; Kim H; Heron DE; Selvaraj R
    Technol Cancer Res Treat; 2006 Oct; 5(5):521-7. PubMed ID: 16981795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
    de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
    Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.